HEPION PHARMACEUTICALS, INC. Foreign Currency Transaction Gain (Loss), before Tax
HEPION PHARMACEUTICALS, INC. (HEPA) reported Foreign Currency Transaction Gain (Loss), before Tax of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-03-12
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $100.00K, a 267.73% increase year-over-year.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was $100.00K, a 490.25% increase from fiscal 2022.
- HEPION PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was $16.94K, a 87.68% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $100.00K derived: sum of 2 quarters · filed 2026-03-12 | $100.00K derived: sum of 3 quarters · filed 2026-03-12 | $100.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $27.19K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $27.19K derived: sum of 3 quarters · filed 2026-03-12 | $47.60K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-19 | $27.19K derived: sum of 2 quarters · filed 2026-03-12 | $47.60K derived: sum of 3 quarters · filed 2026-03-12 | $124.73K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $27.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $47.60K derived: sum of 2 quarters · filed 2026-03-12 | $124.73K derived: sum of 3 quarters · filed 2026-03-12 | $100.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $20.40K 10-Q · filed 2025-11-12 | $97.54K derived: sum of 2 quarters · filed 2025-11-12 | $72.81K 10-Q · filed 2025-11-12 | $211.55K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $77.13K 10-Q · filed 2025-08-14 | $52.40K 10-Q · filed 2025-08-14 | $191.15K derived: sum of 3 quarters · filed 2025-08-14 | $250.58K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $129.54K 10-Q · filed 2025-05-19 | $114.01K derived: sum of 2 quarters · filed 2025-05-19 | $173.44K derived: sum of 3 quarters · filed 2025-05-19 | $204.10K derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | -$15.53K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | $43.91K derived: sum of 2 quarters · filed 2025-04-08 | $74.57K derived: sum of 3 quarters · filed 2025-04-08 | $100.00K 10-K · filed 2025-04-08 |
| 2023-09-30 | $59.43K 10-Q · filed 2024-11-14 | $90.09K derived: sum of 2 quarters · filed 2024-11-14 | $115.53K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $30.66K 10-Q · filed 2024-08-13 | $56.09K 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | $16.94K 10-K · filed 2024-04-16 | |||
| 2021-12-31 | $137.46K 10-K · filed 2023-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |